By Duke Medicine News and Communications
Published: August 4, 2011
A discovery by scientists at Duke University Medical Center and Johns Hopkins University could increase the chances for an effective combination of drug therapy to treat the second most common type of brain tumor.
For years scientists have been looking for the primary cancer genes involved in the development of oligodendrogliomas. Scientists knew the two chromosomes that held the probable mutations, but not the particular gene information.
Now scientists at Duke and Johns Hopkins have discovered the most likely genetic mutations that researchers have been hunting for on chromosomes 1 and 19. These genes were difficult to find until the technology improved, said Hai Yan, MD, PhD, Duke associate professor of pathology and co-corresponding author of the study.
"The team used whole genome sequencing technology so that no genes would be excluded, and we found to our surprise that one gene, on chromosome 19, was mutated in six out of the seven initial tumor specimens we sequenced," Yan said. "A mutation frequency of 85 percent is very high."
The study was published in the August 4 ahead-of-print issue of the journal Science.
"Whenever we find genes mutated in a majority of tumors, it is likely that the pathway regulated by that gene is critical for the development and biology of the tumor," says Nickolas Papadopoulos, PhD, co-corresponding author and associate professor of oncology at the Johns Hopkins Kimmel Cancer Center.
The finding of two additional new genes involved in oligodendrogliomas increases the chances for an effective combination drug therapy for the tumor, Yan said. He envisions a combination cocktail of drugs similar to the combination-drug treatments taken by HIV patients that would target different pathways involved in cancer, and assist in reducing the chance of relapsing, increasing odds of success.
The genes they identified are tumor suppressor genes. The cancer-related pathways that involve these genes could become targets for future treatments, Yan said.
"Tumor suppressor genes like the ones we found, CIC or FUBP1, won't be targeted directly by small molecules, because the mutated gene products result in loss of function, but the pathways that these genes are involved in could be targeted," Yan said.
"Another very important feature is that the genes could be used as biomarkers to distinguish this type of cancer from other types of brain tumors."
The researchers found CIC on chromosome 19 and FUBP1 on chromosome 1 based on an initial study of seven oligodendrogliomas; they found six mutations and two mutations, respectively, in the seven tumors.
Further study of 27 more of these tumors showed that there were 12 and three mutations of CIC and FUBP1, respectively. The two genes were rarely mutated in other types of cancers, indicating that they are oligodendroglioma-specific genes.
These tumors also contained a glioma (brain tumor) gene mutation identified earlier by Yan and colleagues, the IDH mutations.
Other authors included Darell Bigner and Roger McLendon of the Preston Robert Tisch Brain Tumor Center at Duke, the Pediatric Brain Tumor Foundation, and the Department of Pathology at Duke, as well as co-corresponding authors Bert Vogelstein and Kenneth Kinzler of the Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions at Johns Hopkins Kimmel Cancer Center, and lead author Chetan Bettegowda, chief resident in the Department of Neurosurgery at Johns Hopkins in Baltimore.
Other authors were from the Department of Neurosurgery, the Department of Otolaryngology-Head and Neck Surgery, and the Department of Pathology at the Johns Hopkins Medical Institutions; the Department of Neurosurgery at the University of Texas MC Anderson Cancer Center and Baylor College of Medicine, and the Department of Neurology at the University of Sao Paulo in Brazil.
Funding came from the Virginia and D.K. Ludwig Fund for Cancer Research, the Pediatric Brain Tumor Foundation Institute, the Duke Comprehensive Cancer Center Core, the Burroughs Wellcome Fund, The James S. McDonnell Foundation, Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, grants, the NCI Division of Cancer Prevention and NIH contracts, and an NIH/NCI National Research Service Award.
Under agreements between the Johns Hopkins University, Genzyme, Exact Sciences, Inostics, Qiagen, Invitrogen and Personal Genome Diagnostics, some of the Johns Hopkins researchers are entitled to a share of the royalties received by the University on sales of products related to genes and technologies described in this manuscript.